Collection |

Editor's Highlights | Breast Cancer Awareness Month

In support of Breast Cancer Awareness Month, Editor-in-Chief Dr. Larry Norton, Medical Director of the Evelyn H. Lauder Breast Center at Memorial Sloan Kettering Cancer Center, has curated a collection of research highlights from npj Breast Cancer. The collection includes research on prognostic markers, cancer genomics, metastasis, therapeutics, and more. 

Research Highlights

Patients with the most common form of breast cancer stand to benefit from taking a drug that blocks two cell cycle–regulating proteins in addition to hormonal therapy. In a phase III clinical trial, Stephen Johnston from the Royal Marsden NHS Foundation Trust
in London, UK, and colleagues randomly gave 493 postmenopausal women with HR+/HER2− metastatic breast cancer a nonsteroidal aromatase inhibitor plus either a placebo or a drug called abemaciclib, a targeted inhibitor of CDK4 and CDK6. A planned interim analysis previously showed that abemaciclib was safe and effective. Johnson’s team now reports that abemaciclib nearly doubled the time women live without disease recurrence, from 15 months on placebo to 28 months on the drug. Additionally, responses were more common and lasted longer among women who received both abemaciclib and the hormonal therapy.

Article | Open Access | | npj Breast Cancer